Brea C. Lipe, MD

Brea C. Lipe, MD closes this series highlighting the vast landscape of effective treatments and those on the horizon.

Brea C. Lipe, MD reflects on how the PERSEUS trial results may affect future treatment approaches.

Brea C. Lipe, MD explains common grade 3 and grade 4 adverse events observed in the PERSEUS trial.

Brea C. Lipe, MD highlights key takeaways and patient outcomes from the PERSEUS phase three trial.

Brea C. Lipe, MD explains the trial design and patient population of PERSEUS phase three trial.

Brea C. Lipe, MD describes the unique treatment technology explored in the PERSEUS phase three trial.

Brea C. Lipe, MD, discusses the evolving landscape of multiple myeloma treatment, highlighting the current abundance of drugs and the challenges associated with optimizing their use.

"I think it’s important to know that this can change over time, what is defined as transplant eligibility, so getting the transplant center involved early can be helpful."